Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysis
Lisa G Schoof(Amsterdam Neuroscience), Jeppe Romme Christensen(Aarhus University Hospital), Emmanuelle Le Page(Centre Hospitalier Universitaire de Rennes), Malo Gaubert(Centre National de la Recherche Scientifique), Finn Sellebjerg(Danish Multiple Sclerosis Center), Bas Jasperse(Vrije Universiteit Amsterdam), Øivind Torkildsen(Haukeland University Hospital), Henrik Lundell(Hvidovre Hospital), Eva Strijbis(Amsterdam University Medical Centers), Birgit I. Lissenberg‐Witte(OLVG), Vanessa Wiggermann(Copenhagen University Hospital), Brit Ellen Rød(Haukeland University Hospital), Hartwig R. Siebner(Universität Hamburg), Einar August Høgestøl(Anna Needs Neuroblastoma Answers), Sahla El Mahdaoui(Copenhagen University Hospital), Bob W. van Oosten(Amsterdam Neuroscience), Tim Friede(FIND), Menno M. Schoonheim(Amsterdam Neuroscience), Laure Michel(Centre Hospitalier Universitaire de Rennes), Gilles Edan(Centre National de la Recherche Scientifique), Anne Kerbrat(Centre Hospitalier Universitaire de Rennes), Karam Sidaros(Copenhagen University Hospital), Zehao Su(University of Copenhagen), Josephine Sandahl Michelsen(Danish Multiple Sclerosis Center), Kjell-Morten Myhr(Haukeland University Hospital), Frank Eriksson(University of Copenhagen), Henning Hoel Rise(University of Oslo)
Cited by 3
Related Papers
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|957